Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Location
San Jose, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.8 % -70.4%
Debt-to-equity -7.64 % -2.4%
Return On Equity 4.93 %
Return On Assets -1.29 % -1.3%
Operating Margin -37.28 %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 51,900,000 USD -4.1%
Weighted Average Number of Shares Outstanding, Basic 46,444,000 shares +61.1%
Weighted Average Number of Shares Outstanding, Diluted 46,444,000 shares +61.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1,200,000 USD
Research and Development Expense 22,105,000 USD -19.6%
General and Administrative Expense 20,113,000 USD -17.3%
Operating Income (Loss) -44,732,000 USD +13.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67,883,000 USD -7.3%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -28,315,000 USD -0.52%
Earnings Per Share, Basic 0 USD/shares +26.4%
Earnings Per Share, Diluted 0 USD/shares +26.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4,144,000 USD -3.1%
Accounts Receivable, after Allowance for Credit Loss, Current 600,000 USD
Assets, Current 4,955,000 USD -84.7%
Property, Plant and Equipment, Net 922,000 USD -83.2%
Operating Lease, Right-of-Use Asset 4,017,000 USD -26%
Other Assets, Noncurrent 245,000 USD -0.41%
Assets 10,139,000 USD -76.7%
Accounts Payable, Current 2,467,000 USD +57.5%
Liabilities, Current 19,144,000 USD -5.3%
Operating Lease, Liability, Noncurrent 2,968,000 USD -26.1%
Liabilities 22,112,000 USD -41.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3,000 USD -62.5%
Retained Earnings (Accumulated Deficit) -122,275,000 USD -30.1%
Stockholders' Equity Attributable to Parent -7,860,000 USD -3.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -11,973,000 USD -3.1%
Liabilities and Equity 10,139,000 USD -76.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8,149,000 USD +13.3%
Net Cash Provided by (Used in) Financing Activities -3,731,000 USD -31.8%
Net Cash Provided by (Used in) Investing Activities 18,229,000 USD +77.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6,349,000 USD +5.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4,644,000 USD -2.8%
Deferred Tax Assets, Valuation Allowance 69,072,000 USD +13.2%
Deferred Tax Assets, Gross 69,072,000 USD +13.2%
Operating Lease, Liability 4,017,000 USD -26%
Payments to Acquire Property, Plant, and Equipment 51,000 USD +1.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28,607,000 USD -1.7%
Lessee, Operating Lease, Liability, to be Paid 4,770,000 USD -28.4%
Property, Plant and Equipment, Gross 5,872,000 USD +31.3%
Operating Lease, Liability, Current 1,049,000 USD -25.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1,229,000 USD -35.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 475,000 USD +2.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 753,000 USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1,278,000 USD +4%
Deferred Tax Assets, Operating Loss Carryforwards 19,384,000 USD +49.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits 661,000 USD +35.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1,330,000 USD +4.1%
Operating Lease, Payments 473,000 USD +1.6%
Additional Paid in Capital 114,406,000 USD +17.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3,925,000 USD +1.4%
Interest Expense 3,671,000 USD -29.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%